no recruitment

Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The control group will receive standard of care alone. The study will test for the effects of the additional IV iron on the symptoms, clinical picture and quality of life of the treated patients.

Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The control group will receive standard of care alone. The study will test for the effects of the additional IV iron on the symptoms, clinical picture and quality of life of the treated patients. The parameters that will be measured will include clinical, lab, echo, and quality of life questionnaires.

Inclusion Criteria:

• Heart failure grade 3-4
• Heart echo EF< 40% (ejection fraction)
• Hb > 10 mg/dL
• Iron> 50 mic/dL
• Iron/ transferrin rate > 20%

Exclusion Criteria:

• Infection
• Acute ischemia
• Patients that didn't receive the standard of care during 3 days before investigational product administration
• Hemochromatosis
• Known allergy to one of the products of the investigational product.
• Macrocytic anemia
• Iron excess
• Pregnant women
• Mentally disabled patients which can't give their concent properly.